We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Innovacell Includes First Patients in a Phase IIb Study for its Cell Therapy Product urocell®
News

Innovacell Includes First Patients in a Phase IIb Study for its Cell Therapy Product urocell®

Innovacell Includes First Patients in a Phase IIb Study for its Cell Therapy Product urocell®
News

Innovacell Includes First Patients in a Phase IIb Study for its Cell Therapy Product urocell®

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Innovacell Includes First Patients in a Phase IIb Study for its Cell Therapy Product urocell®"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"First patient in" is the call from the Innsbruck firm, Innovacell Biotechnologie AG, as the first patient was recruited at the MHAT Plovdiv clinic in Bulgaria for the Phase IIb study of the advanced therapy medicinal product, urocell®. The clinical study will be conducted, beside Bulgaria, in the Czech Republic, Germany, Poland and Romania at more than 50 clinics.

"Altogether in this controlled clinical study, some 245 patients will participate. The study objective is to determine the optimal dose for treatment and to evaluate the effectiveness in the indication of Stress Urinary Incontinence," explained Innovacell CEO, Ekkehart Steinhuber. Initial evidential results are expected for the fourth quarter of 2010. Innovacell is investing 10 million Euro in the Phase IIb study.

Innovative therapy
urocell® is based on a therapy concept for the treatment of bladder weakness, aimed at people with damaged sphincters. In contrast to earlier types of therapy, that rely either on "bulking" methods or on surgical "lifting" of the urogenital tract, urocell® is based on the principle of the body's own ability to regenerate the sphincter muscle by using the patient's own muscle cells.

Phase IIb study
Immediately after completion of the Phase IIb study, Innovacell will start with the Phase III study. Said Steinhuber: "Its findings will be available in 2011. When the results are established, we will apply for an EU-Marketing Authorization at the European Medicines Agency (EMEA) in London."
Advertisement